Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Sponsor: Zenas BioPharma (USA), LLC
Summary
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for approximately 30 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
Official title: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
705
Start Date
2026-03-23
Completion Date
2030-07
Last Updated
2026-05-29
Healthy Volunteers
No
Interventions
Orelabrutinib
Orally
Placebo
Orally
Locations (11)
Arizona Neuroscience Research, LLC
Pheonix, Arizona, United States
Perseverance Research Center
Scottsdale, Arizona, United States
Regina Berkovich MD, PhD Inc.
West Hollywood, California, United States
Nova Clinical Research, LLC
Bradenton, Florida, United States
Neurology Associates, PA
Maitland, Florida, United States
Washington University School of Medicine
St Louis, Missouri, United States
Velocity Clinical Research, Raleigh Neurology
Raleigh, North Carolina, United States
Premier Neurology
Greenville, South Carolina, United States
Neurology Clinic, P.C.
Cordova, Tennessee, United States
Lone Star Neurology
San Antonio, Texas, United States
Texas Institute for Neurological Disorders
Sherman, Texas, United States